Capital Research Global Investors Alnylam Pharmaceuticals, Inc. Transaction History
Capital Research Global Investors
- $466 Billion
- Q4 2024
A detailed history of Capital Research Global Investors transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Capital Research Global Investors holds 6,968,513 shares of ALNY stock, worth $1.85 Billion. This represents 0.35% of its overall portfolio holdings.
Number of Shares
6,968,513
Previous 5,243,903
32.89%
Holding current value
$1.85 Billion
Previous $1.44 Billion
13.68%
% of portfolio
0.35%
Previous 0.31%
Shares
9 transactions
Others Institutions Holding ALNY
# of Institutions
686Shares Held
110MCall Options Held
1.23MPut Options Held
1.19M-
Capital World Investors Los Angeles, CA16.6MShares$4.4 Billion0.62% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.7MShares$3.37 Billion0.05% of portfolio
-
Black Rock Inc. New York, NY9.55MShares$2.53 Billion0.05% of portfolio
-
Wellington Management Group LLP Boston, MA4.2MShares$1.11 Billion0.19% of portfolio
-
Baillie Gifford & CO4.04MShares$1.07 Billion0.75% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $32.6B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...